1. Home
  2. LGVN
  3. LGVN News

Latest Longeveron Inc. (LGVN) News on June 7, 2025

Here's Why Longeveron (NASDAQ:LGVN) Must Use Its Cash Wisely
LGVN

Simply Wall St.

9 days ago

Here's Why Longeveron (NASDAQ:LGVN) Must Use Its Cash Wisely

Longeveron® to Attend BIO International Convention 2025
LGVN

GlobeNewswire

18 days ago

Longeveron® to Attend BIO International Convention 2025

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient
LGVN

GlobeNewswire

a month ago

Longeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient

LGVN

Zacks Small Cap Research

a month ago

LGVN Entering Crucial Period in Great Shape

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update
LGVN

GlobeNewswire

a month ago

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

Longeveron Inc (LGVN) Q1 2025: Everything You Need To Know Ahead Of Earnings
LGVN

GuruFocus.com

a month ago

Longeveron Inc (LGVN) Q1 2025: Everything You Need To Know Ahead Of Earnings

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
LGVN

GlobeNewswire

a month ago

Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025
LGVN

GlobeNewswire

2 months ago

Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025

LGVN

MT Newswires

2 months ago

Longeveron Files $70 Million Mixed Shelf

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease
LGVN

GlobeNewswire

3 months ago

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease

LGVN

Zacks Small Cap Research

3 months ago

LGVN Announces Positive Alzheimer’s News

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease
LGVN

GlobeNewswire

3 months ago

Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease

Longeveron® to Present at the 37th Annual Roth Conference
LGVN

GlobeNewswire

3 months ago

Longeveron® to Present at the 37th Annual Roth Conference

LGVN

Zacks Small Cap Research

3 months ago

LGVN Well Positioned for Critical 2025

Analysts Expect Breakeven For Longeveron Inc. (NASDAQ:LGVN) Before Long
LGVN

Simply Wall St.

3 months ago

Analysts Expect Breakeven For Longeveron Inc. (NASDAQ:LGVN) Before Long

Longeveron Full Year 2024 Earnings: Beats Expectations
LGVN

Simply Wall St.

3 months ago

Longeveron Full Year 2024 Earnings: Beats Expectations

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update
LGVN

GlobeNewswire

3 months ago

Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

Longeveron Inc (LGVN) Q4 2024 Earnings Report Preview: What To Look For
LGVN

GuruFocus.com

3 months ago

Longeveron Inc (LGVN) Q4 2024 Earnings Report Preview: What To Look For

Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025
LGVN

GlobeNewswire

4 months ago

Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025

Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now
LGVN

GlobeNewswire

4 months ago

Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

LGVN

MT Newswires

4 months ago

Longeveron Cellular Therapy Granted International Non-Proprietary Name

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™
LGVN

GlobeNewswire

4 months ago

Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™

Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025
LGVN

GlobeNewswire

4 months ago

Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025

Longeveron to Present at Biotech Showcase 2025
LGVN

GlobeNewswire

6 months ago

Longeveron to Present at Biotech Showcase 2025

Longeveron initiated with a Buy at Roth MKM
LGVN

TipRanks

6 months ago

Longeveron initiated with a Buy at Roth MKM

Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now
LGVN

GlobeNewswire

6 months ago

Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now

Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024
LGVN

GlobeNewswire

6 months ago

Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024

We're Keeping An Eye On Longeveron's (NASDAQ:LGVN) Cash Burn Rate
LGVN

Simply Wall St.

7 months ago

We're Keeping An Eye On Longeveron's (NASDAQ:LGVN) Cash Burn Rate

LGVN

Zacks Small Cap Research

7 months ago

LGVN Highlights Potential Groundbreaking Treatments

Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update
LGVN

GlobeNewswire

7 months ago

Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update

LGVN

MT Newswires

7 months ago

Longeveron Names Devin Blass Chief Technology Officer

Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)
LGVN

GlobeNewswire

7 months ago

Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

Earnings To Watch: Longeveron Inc (LGVN) Reports Q3 2024 Result
LGVN

GuruFocus.com

7 months ago

Earnings To Watch: Longeveron Inc (LGVN) Reports Q3 2024 Result

Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
LGVN

GlobeNewswire

7 months ago

Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
LGVN

GlobeNewswire

7 months ago

Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)

LGVN

Zacks Small Cap Research

7 months ago

LGVN Announces Treatment Garners Excellent Results

Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
LGVN

GlobeNewswire

7 months ago

Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting

Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
LGVN

GlobeNewswire

8 months ago

Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)

LGVN

MT Newswires

8 months ago

Longeveron to Present 5-Year Survival Data for Hypoplastic Left Heart Syndrome Therapy

Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
LGVN

GlobeNewswire

8 months ago

Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting

Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day
LGVN

GlobeNewswire

8 months ago

Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day

Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
LGVN

GlobeNewswire

8 months ago

Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Longeveron to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa
LGVN

GlobeNewswire

8 months ago

Longeveron to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa

Longeveron® Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B™ in Hypoplastic Left Heart Syndrome (HLHS)
LGVN

GlobeNewswire

9 months ago

Longeveron® Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B™ in Hypoplastic Left Heart Syndrome (HLHS)

Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference
LGVN

GlobeNewswire

9 months ago

Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference

LGVN

Zacks Small Cap Research

10 months ago

LGVN Solidifies Financials so Treatment Can Advance

Longeveron® Announces Second Quarter 2024 Financial Results and Provides Business Update
LGVN

GlobeNewswire

10 months ago

Longeveron® Announces Second Quarter 2024 Financial Results and Provides Business Update

Longeveron® to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024
LGVN

GlobeNewswire

10 months ago

Longeveron® to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024

Why Is Alzheimer's-Focused Longeveron Stock Trading Higher On Monday?
LGVN

Benzinga

10 months ago

Why Is Alzheimer's-Focused Longeveron Stock Trading Higher On Monday?

Longeveron’s Phase IIa Alzheimer’s therapy trial meets efficacy endpoints
LGVN

Clinical Trials Arena

10 months ago

Longeveron’s Phase IIa Alzheimer’s therapy trial meets efficacy endpoints

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC)
LGVN

GlobeNewswire

10 months ago

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC)

Bullish Longeveron Insiders Loaded Up On US$734.3k Of Stock
LGVN

Simply Wall St.

10 months ago

Bullish Longeveron Insiders Loaded Up On US$734.3k Of Stock

LGVN

MT Newswires

a year ago

Longeveron Raises $9 Million From Direct Offering

Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
LGVN

GlobeNewswire

a year ago

Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

LGVN

MT Newswires

a year ago

Longeveron Shares Decline After Pricing of $9 Million Direct Offering

Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
LGVN

GlobeNewswire

a year ago

Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

LGVN

MT Newswires

a year ago

Longeveron Receives FDA's Fast Track Designation for Lomecel-B as Alzheimer's Treatment

Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease
LGVN

GlobeNewswire

a year ago

Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease

LGVN

Zacks Small Cap Research

a year ago

LGVN Gets Great FDA News for Alzheimer's Drug

LGVN

Zacks Small Cap Research

a year ago

OTC Markets Hosts Virtual Investor Presentation with Wa’el Hashad, CEO of Longeveron, and Brad Sorensen, Senior Analyst at Zacks SCR

Why Is Longeveron Stock Soaring On Wednesday?
LGVN

Benzinga

a year ago

Why Is Longeveron Stock Soaring On Wednesday?

Longeveron scores RMAT designation for Alzheimer’s cell therapy
LGVN

Pharmaceutical Technology

a year ago

Longeveron scores RMAT designation for Alzheimer’s cell therapy

LGVN

Zacks Small Cap Research

a year ago

LGVN’s Alzheimer's Treatment Gets FDA Boost

LGVN

MT Newswires

a year ago

Longeveron Receives FDA's Regenerative Medicine Advanced Therapy Designation for Lomecel-B; Shares Rise in Premarket

Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease
LGVN

GlobeNewswire

a year ago

Longeveron® Announces U.S. FDA Grants Lomecel-B™ Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer’s Disease

Neha Motwani Elected to Longeveron® Board of Directors
LGVN

GlobeNewswire

a year ago

Neha Motwani Elected to Longeveron® Board of Directors

Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors
LGVN

GlobeNewswire

a year ago

Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors

Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
LGVN

GlobeNewswire

a year ago

Life Science Virtual Investor Forum Presentations Now Available for Online Viewing

Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction
LGVN

GlobeNewswire

a year ago

Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction

Life Sciences Virtual Investor Forum Agenda Announced for June 20th
LGVN

GlobeNewswire

a year ago

Life Sciences Virtual Investor Forum Agenda Announced for June 20th

Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024
LGVN

GlobeNewswire

a year ago

Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024

Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds
LGVN

GlobeNewswire

a year ago

Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds

LGVN

MT Newswires

a year ago

Top Premarket Gainers

LGVN

MT Newswires

a year ago

Top Premarket Gainers

LGVN

Zacks Small Cap Research

a year ago

LGVN Provides Encouraging Update and Improved Revenue

Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now
LGVN

GlobeNewswire

a year ago

Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now

Longeveron® Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B™ as a Potential Treatment for HLHS, a Rare Pediatric Cardiac Disease
LGVN

GlobeNewswire

a year ago

Longeveron® Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B™ as a Potential Treatment for HLHS, a Rare Pediatric Cardiac Disease

Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now
LGVN

GlobeNewswire

a year ago

Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now

Edge Total Intelligence Inc. Updates Status of MCTO
LGVN

Newsfile

a year ago

Edge Total Intelligence Inc. Updates Status of MCTO

HEATHERWICK STUDIO UNVEILS ICONIC GLASS CANOPY, THE JEWEL IN THE CROWN OF REIMAGINED OLYMPIA
LGVN

CNW Group

a year ago

HEATHERWICK STUDIO UNVEILS ICONIC GLASS CANOPY, THE JEWEL IN THE CROWN OF REIMAGINED OLYMPIA

Nokia introduces Network Exposure Platform to expand and simplify network API exposure for service providers
LGVN

GlobeNewswire

a year ago

Nokia introduces Network Exposure Platform to expand and simplify network API exposure for service providers

LED Driver with CAN Bus for Dynamic Automotive Interior RGB Lighting
LGVN

GlobeNewswire

a year ago

LED Driver with CAN Bus for Dynamic Automotive Interior RGB Lighting

Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY
LGVN

GlobeNewswire

a year ago

Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY

The sale of Aspo's subsidiary ESL Shipping's Supramax vessels has been completed on June 11 2024
LGVN

GlobeNewswire

a year ago

The sale of Aspo's subsidiary ESL Shipping's Supramax vessels has been completed on June 11 2024

Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku
LGVN

CNW Group

a year ago

Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse
LGVN

PR Newswire

a year ago

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse

Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024
LGVN

GlobeNewswire

a year ago

Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
LGVN

Business Wire

a year ago

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus
LGVN

GlobeNewswire

a year ago

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

Share buy-back programme - week 23
LGVN

GlobeNewswire

a year ago

Share buy-back programme - week 23

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?
LGVN

Simply Wall St.

a year ago

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Japan's service sector mood hits nearly 2-year low in May
LGVN

Reuters

a year ago

Japan's service sector mood hits nearly 2-year low in May

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'
LGVN

AFP

a year ago

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share
LGVN

GlobeNewswire

a year ago

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

Enduring role of 'treasuring the past' hailed
LGVN

PR Newswire

a year ago

Enduring role of 'treasuring the past' hailed

LGVN

MT Newswires

a year ago

Longeveron Launches Contract Manufacturing Business

Longeveron® Announces Contract Development and Manufacturing Business and First Contract
LGVN

GlobeNewswire

a year ago

Longeveron® Announces Contract Development and Manufacturing Business and First Contract

Longeveron® to Attend BIO International Convention 2024
LGVN

GlobeNewswire

a year ago

Longeveron® to Attend BIO International Convention 2024

LGVN

Zacks Small Cap Research

a year ago

LGVN Making Great Strides

Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update
LGVN

GlobeNewswire

a year ago

Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update

Share on Social Networks: